This randomized controlled trial aims to compare the efficacy of methotrexate (MTX) monotherapy versus combined methotrexate and selective serotonin reuptake inhibitor (SSRI) therapy in patients with psoriasis and comorbid depression and/or anxiety. Participants will be randomly assigned to two groups: one receiving MTX alone and the other receiving MTX plus escitalopram. Clinical outcomes will be evaluated over a 6-month period, including psoriasis severity using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), quality of life using the Dermatology Life Quality Index (DLQI), and psychological status using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). The study will assess whether combination therapy provides superior clinical and psychological outcomes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety
Methotrexate 0.4mg/kg once weekly for 6 months
Kasralainy
Cairo, Cairo Governorate, Egypt
RECRUITINGcomparison of Percentage change in PASI score from baseline to 6 months between group A and B
Time frame: 6 months
Comparison between percentage change of BDI, BAI, Ham-A and Ham-D in groups A&B
Time frame: 6 months
Comparison of percentage of patients who achieved PASI 75%, 90% & 100% between groups A & B
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.